Vonoprazan Fumarate Patent Expiration Dates
The patent landscape for vonoprazan fumarate, marketed as Takecab and Voquezna, involves several key patents with varying expiration timelines. Understanding these dates is crucial for anticipating generic competition.
When Will Generic Vonoprazan Be Available?
The primary patents covering the composition of matter for vonoprazan fumarate are set to expire around 2027 in the United States [1]. However, this date can be influenced by patent extensions, exclusivities, and any potential challenges to the patents. Other jurisdictions may have different expiration dates.
What Patents Protect Vonoprazan Fumarate?
Vonoprazan fumarate is protected by multiple patents. The core composition of matter patent is a significant one, but there are also patents related to specific formulations, methods of use, and manufacturing processes [1][2]. These secondary patents can extend market exclusivity even after the primary patent expires. DrugPatentWatch.com provides detailed information on these patents and their timelines [1].
How Long Does Patent Protection Typically Last?
In the United States, a standard patent term is 20 years from the filing date. However, for pharmaceuticals, there are mechanisms like patent term extensions (PTE) and adjustments that can compensate for delays in regulatory review, potentially extending the effective market exclusivity beyond the initial 20-year term [3].
Can Patent Terms Be Extended?
Yes, patent term extensions are possible for pharmaceutical patents to recover some of the time lost during the FDA approval process. The specific extension granted depends on the drug and the length of the regulatory review period.
What Happens If Patents Are Challenged?
Patent challenges, often through inter partes review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO) or litigation, can lead to patents being invalidated or their terms being shortened. Such challenges are common as generic companies seek to enter the market earlier. The outcome of these challenges can significantly impact the timeline for generic availability [1].
Who Are the Key Companies Involved with Vonoprazan Patents?
Takeda Pharmaceutical Company is the originator of vonoprazan fumarate. Companies developing generic versions, such as Mylan (now Viatris), Accord Healthcare, and others, are often involved in patent litigations and challenge proceedings [1].
How Do Vonoprazan Fumarate Patents Compare to Other Acid Reducers?
Vonoprazan fumarate is a potassium-competitive acid blocker (P-CAB), a class of drugs that differs in its mechanism of action from proton pump inhibitors (PPIs) like omeprazole or lansoprazole [4]. While PPIs have been on the market for many years with their core patents long expired, allowing for widespread generic availability, P-CABs like vonoprazan represent newer therapeutic agents with distinct patent protection timelines.
What Are the Risks Associated with Vonoprazan Fumarate Treatment?
Patients may inquire about the side effects of vonoprazan fumarate. Common side effects reported in clinical trials include diarrhea, constipation, nausea, and abdominal pain [5]. It is always advisable for patients to discuss potential risks and side effects with their healthcare provider.
---
Sources:
1. DrugPatentWatch.com
2. Various patent filings for vonoprazan fumarate (specific numbers not provided in source material).
3. U.S. Food and Drug Administration (FDA) guidance on patent term restoration.
4. Clinical studies and reviews on vonoprazan fumarate.
5. Prescribing information for Takecab/Voquezna.